Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.147CHF
−113.76 MCHF
700.50 KCHF
25.71 M
About Inovio Pharmaceuticals, Inc.
Sector
CEO
Jacqueline E. Shea
Headquarters
Plymouth Meeting
Website
Employees (FY)
122
Founded
1983
FIGI
BBG00LVDLC19
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange INOVIO PHARMACEUTI stocks are traded under the ticker GBM.
INOVIO PHARMACEUTI is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
GBM stock is 0% volatile and has beta coefficient of 1.69. Track INOVIO PHARMACEUTI stock price on the chart and check out the list of the most volatile stocks — is INOVIO PHARMACEUTI there?
GBM earnings for the last quarter are −0.93 CHF per share, whereas the estimation was −1.00 CHF resulting in a 7.25% surprise. The estimated earnings for the next quarter are −0.90 CHF per share. See more details about INOVIO PHARMACEUTI earnings.
INOVIO PHARMACEUTI revenue for the last quarter amounts to 86.72 K CHF despite the estimated figure of 303.10 K CHF. In the next quarter revenue is expected to reach 135.32 K CHF.
Yes, you can track INOVIO PHARMACEUTI financials in yearly and quarterly reports right on TradingView.
GBM stock hasn't changed in a week, the last month showed zero change in price, over the last year there was no change in INOVIO PHARMACEUTI price.
GBM net income for the last quarter is −21.05 M CHF, while the quarter before that showed −31.06 M CHF of net income which accounts for 32.23% change. Track more INOVIO PHARMACEUTI financial stats to get the full picture.
Today INOVIO PHARMACEUTI has the market capitalization of 262.62 M, it has increased by 17.61% over the last week.
No, GBM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GBM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INOVIO PHARMACEUTI stock right from TradingView charts — choose your broker and connect to your account.
As of May 8, 2024, the company has 122.00 employees. See our rating of the largest employees — is INOVIO PHARMACEUTI on this list?
We've gathered analysts' opinions on INOVIO PHARMACEUTI future price: according to them, GBM price has a max estimate of 35.12 CHF and a min estimate of 7.02 CHF. Watch GBM chart and read a more detailed INOVIO PHARMACEUTI stock forecast: see what analysts think of INOVIO PHARMACEUTI and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INOVIO PHARMACEUTI EBITDA is −109.39 M CHF, and current EBITDA margin is −15.83 K%. See more stats in INOVIO PHARMACEUTI financial statements.